Profile data is unavailable for this security.
About the company
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
- Revenue in USD (TTM)47.00k
- Net income in USD-46.47m
- Incorporated2014
- Employees23.00
- LocationCheckpoint Therapeutics Inc95 SAWYER ROAD, SUITE 110WALTHAM 02453United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://checkpointtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instil Bio Inc | 0.00 | -75.17m | 170.08m | 49.00 | -- | 0.9677 | -- | -- | -11.56 | -11.56 | 0.00 | 27.02 | 0.00 | -- | -- | 0.00 | -24.53 | -- | -25.52 | -- | -- | -- | -- | -- | -- | -492.20 | 0.3179 | -- | -- | -- | 30.06 | -- | -- | -- |
| Nkarta Inc | 0.00 | -110.61m | 172.89m | 159.00 | -- | 0.4013 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Galectin Therapeutics Inc | 0.00 | -45.23m | 173.13m | 14.00 | -- | -- | -- | -- | -0.7284 | -0.7284 | 0.00 | -1.48 | 0.00 | -- | -- | 0.00 | -176.31 | -92.08 | -587.13 | -121.97 | -- | -- | -- | -- | -- | -7.18 | 8.66 | -- | -- | -- | -15.26 | -- | -- | -- |
| Actuate Therapeutics Inc | -100.00bn | -100.00bn | 175.39m | 11.00 | -- | 32.73 | -- | -- | -- | -- | -- | 0.2744 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0703 | -- | -- | -- | -22.74 | -- | -- | -- |
| Verastem Inc | 10.00m | -93.45m | 178.03m | 73.00 | -- | 14.56 | -- | 17.80 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.50m | 178.11m | 3.00 | -- | 35.75 | -- | -- | -0.8111 | -0.8111 | 0.00 | 0.3791 | 0.00 | -- | -- | 0.00 | -140.17 | -36.43 | -151.72 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 178.25m | 14.00 | -- | 1.16 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 180.52m | 59.00 | -- | 2.18 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 182.92m | 158.00 | -- | 0.6505 | -- | 15.94 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 47.00k | -46.47m | 183.12m | 23.00 | -- | -- | -- | 3,896.21 | -1.44 | -1.44 | 0.0013 | -0.2749 | 0.0127 | -- | -- | 2,043.48 | -1,256.40 | -142.43 | -- | -342.79 | -- | -- | -98,868.09 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| 2Seventy Bio Inc | 45.62m | -94.55m | 185.91m | 274.00 | -- | 0.8152 | -- | 4.08 | -1.85 | -1.85 | 0.8659 | 4.43 | 0.0797 | -- | 2.18 | 166,496.30 | -16.52 | -- | -18.31 | -- | 65.72 | 91.76 | -207.25 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 188.54m | 140.00 | -- | 1.67 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -110.66m | 189.41m | 119.00 | -- | 0.626 | -- | -- | -2.50 | -2.50 | 0.00 | 7.01 | 0.00 | -- | -- | 0.00 | -51.27 | -- | -57.66 | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| ADC Therapeutics SA | 70.72m | -212.15m | 192.41m | 273.00 | -- | -- | -- | 2.72 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 193.68m | 137.00 | -- | 3.96 | -- | 2.08 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Data as of Nov 22 2024. Currency figures normalised to Checkpoint Therapeutics Inc's reporting currency: US Dollar USD
15.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 3.89m | 8.77% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.36m | 3.07% |
| Geode Capital Management LLCas of 30 Sep 2024 | 427.65k | 0.97% |
| B. Riley Wealth Advisors, Inc.as of 30 Jun 2024 | 229.20k | 0.52% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 202.77k | 0.46% |
| PVG Asset Management Corp.as of 30 Jun 2024 | 137.19k | 0.31% |
| Wealth Enhancement Advisory Services LLCas of 30 Sep 2024 | 130.00k | 0.29% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 94.42k | 0.21% |
| Susquehanna Financial Group LLLPas of 30 Sep 2024 | 92.14k | 0.21% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 91.00k | 0.21% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
